Skip to main content
    Assistive Tools | Loop | Staff | Library | Vacancies | What's On
Home Dublin City University
  • Courses
    • DCU Open Days
    • Study at DCU
    • Undergraduate
    • CAO Hub
    • Postgraduate Hub
    • DCU Micro-Credentials
    • Scholarships
    • Admissions Information
    • Accommodation
    • Graduate Studies Office
    • Student Recruitment
  • Research
    • Research at DCU
    • DCU Research Portal
    • Research Support Services
    • Research Impact
    • Graduate Studies Office
    • DCU:Innovate Hub
    • DCU:Innovate Enterprise
    • Life Sciences Institute
  • DCU Global
  • Engagement
    • INTRA Internships
    • Courses with INTRA
    • Engagement
      • DCU Engagement
      • The Engagement Hub
      • DCU Alumni
      • DCU in the Community
      • DCU Arts and Culture
      • Age Friendly University
    • DCU Placement
    • DCU Educational Trust
    • DCU International Academy
    • Centre for Talented Youth, Ireland
    • National Institute for Digital Learning
    • DCU Campus Store
    • DCU Sport
    • The Helix
    • Changemaker Schools Network
  • Support
    • Student Support & Development
      • Counselling & Personal Development
      • Student Health Service
      • Student Policies
      • Financial Assistance Service
      • Chaplaincy
      • House of Accessibility
    • Student Advice Centre
    • DCU Healthy
    • Accessible Campus
    • Registry
    • Transcripts
    • Current Students
      • Orientation
      • Examinations
      • Examination Results
      • Fees Information
      • Academic Calendars
      • Digital Technology Solutions (DTS)
    • Student Life
      • DCU Students Union
      • Clubs & Societies
      • DCUFM
    • DCU Autism Friendly
    • Disability & Learning Support Service
    • DCU Access
    • Mature Students
    • Careers Service
    • International Students
  • Faculties
    • DCU Business School
    • DCU Institute of Education
    • Faculty of Engineering & Computing
    • Faculty of Humanities & Social Sciences
    • Faculty of Science & Health
    • DCU Connected
  • More
    • Office of the President
      • DCU Strategic Plan (2023-2028)
    • Office of the COO
      • OCOO
      • Sustainability at DCU
      • DCU Governing Authority
      • Estates
      • Freedom of Information
      • Health & Safety
      • Oifig na Gaeilge
      • University Policies
    • Office of the Vice President of Academic Affairs
      • Graduate Studies
      • DCU SIS
    • Office of the Executive Director of Engagement
    • Office of the Vice President for Research
    • Offices & Departments
      • Communications, Marketing & Events
      • Estates
      • Finance
      • DCU People
      • Digital Technology Solutions (DTS)
      • Language Translation Services
      • Registry
      • Quality and Institutional Insights Office
      • Teaching Enhancement Unit (TEU)
    • Campus
      • How to get here
      • Inter-Faith Centre
      • Parking
      • Pharmacy
  • Home
  • Primary School students
  • Secondary School students
  • Programmes
  • Research
  • Events
  • Contact Us
  • Home
  • Framework
  • Policies
  • Classification Calculator
  • Guidelines
  • Training
  • Contact
  • Home
  • Programme
  • Committees
  • Your visit
  • Contact
  • Home
  • People
  • About Us
  • Research
  • Annual Conference
  • Contact Us
  • Home
  • Student Hub
  • Research Hub
  • Learning Support
  • Visit and Study
  • Find and Borrow
  • Ask Us
  • Home
  • Our Story
  • Cancer Research
  • Our People
  • Work With Us
  • Research
  • Contact Us
<< Back to LSI Cancer Research
LSI Cancer Research

Proteomics Projects

Decoding the TP53 enigma: Investigating the impact of TP53 mutations on non-transcriptional regulation of calcium-mediated apoptotic sensitivity in Triple Negative Breast Cancer.
Shows Dr Alex Eustace and Paul Buchanan in the lab

This study tests a simple idea: that pairing these ADCs with the right partner drugs could make them work better. The team is examining combinations involving Dato‑DXd for ovarian cancer, and T‑DXd for cancers of the oesophagus, stomach, and endometrium.



Why It Matters

To understand and more effectively treat TP53 mutations that interfere with calcium signalling, a process which strengthens cancer cells.

Patient Focus
Identifying novel treatment options for patients with triple negative breast cancer
Cancer Type
Breast Cancer
Expertise
2D and 3D cell culture systems, Proteomics, Bioinformatics, Drug screening platforms
Funders
BioDesign Europe
Principal Investigator(s)
Alex Eustace, Paul Buchanan
Team Members
Tara King
Additional Links
View Project Page   
Novel biotherapeutic strategies to improve cancer treatment by targeting nerve-tumour interactions
Shows project team

Cancer treatment has changed dramatically in recent years, but the way doctors manage cancer‑related pain has barely budged. Much of that stagnation stems from a simple problem: scientists still do not fully understand how tumours and the nervous system interact.A new multidisciplinary effort hopes to change that. By bringing together specialists in cancer biology, neurobiology, pain research and calcium signalling, the project aims to illuminate how tumour cells and nerve cells influence one another—both during normal growth and under the assault of chemotherapy. The hope is that new laboratory models will reveal the hidden mechanisms that drive both pain and cancer progression.Armed with those insights, the team plans to test existing and experimental biologic drugs, alone and in combination, to see whether they can tackle tumour growth and cancer pain at the same time. The ambition is not merely to ease suffering, but to rethink how pain and cancer biology can be targeted together rather than treated as separate problems.



Why It Matters

To elucidate mechanisms and mediators of crosstalk between cancer cells and neurons in both pathology and treatment paradigms, to identify novel biotherapeutic targets, and devise better strategies for the application and toleration of existing therapies that could improve patient outcomes.
 

Patient Focus
Trying to understand how nerve tumour interactions cause pain in cancer, and identify novel treatment options to reduce cancer associated pain.
Cancer Type
Prostate Cancer
Expertise
Immunohistochemistry (IHC), 2D and 3D cell culture systems, In vivo models, Drug screening platforms, Proteomics, Live cell imaging and Microscopy
Funders
Research Ireland and School of Biotechnology
Principal Investigator(s)
Alex Eustace, Gary Lawrence, Paul Buchanan
Team Members
Margherita Obinu
Additional Links
View Project Page   
Targeting the DNA damage response in hard to treat cancers
Shows project team

For patients with glioblastoma, pancreatic or endometrial cancers, the hunt for effective treatments is often a race against biology. One promising avenue lies in the cell’s own repair machinery. Every cell relies on a DNA‑damage response system to fix routine wear and tear. When cancer disrupts part of that system, it creates an Achilles heel. Researchers are now exploiting this vulnerability through “synthetic lethality,” a strategy that targets the remaining repair pathways the tumour still depends on.By blocking those last‑ditch survival tools, the cancer cell is pushed past its limits, unable to recover from the damage it accumulates. Healthy cells, with intact repair systems, are largely spared. The hope is that these genetic weak spots can be turned into a guidebook for new therapies—precise combinations that strike tumours where they are most fragile and offer patients with the toughest cancers a better chance.



Why It Matters

Mutations that dysregulate the DNA damage response (DDR) are often pivotal in determining whether a cancer cell survives or succumbs to treatment. By identifying novel combinatorial therapies that exploit these vulnerabilities through synthetic lethality, we can develop more effective strategies for treating refractory cancers and significantly improve patient outcomes.

Patient Focus
Trying to understand how somatic mutations dysregulate the DNA damage repair pathway, and identify novel therapeutic strategies to target these cancers
Cancer Type
Glioblastoma, Pancreatic Cancer, Endometrial Cancer
Expertise
2D and 3D cell culture systems, Proteomics, In vivo models, Live cell imaging and Microscopy
Funders
CCRT
Principal Investigator(s)
Alex Eustace
Team Members
Anita White
Additional Links
View Project Page   
  • Student Apps
  • Student Email
  • Staff Apps
  • Staff Email
  • Contact Us
  • Loop
  • Disclaimer
  • Privacy and Cookies
  • Accessibility Statement
  • AI in DCU
Facebook Icon
YouTube Icon
Instagram Icon
Tik Tok Icon
LinkedIn Icon
Bluesky Icon
  • The Helix logo
  • ESF logo
  • EU Structural Funds logo
Dublin City University is a registered charity with the Charities Regulatory Authority, RCN 20013653.